ubiquitin–proteasome system

KRAS G12D: How Direct Inhibition Is Advancing Toward Targeted Degradation

KRAS G12D is an important driver mutation in solid tumors such as pancreatic, colorectal, and lung cancers. The emergence of molecules such as MRTX1133 has demonstrated that KRAS G12D can be directly targeted pharmacologically, whereas targeted protein degradation technologies such as PROTACs ...